Avanir Pharmaceuticals, Inc.
) reported that results from a pharmacokinetic (PK) study of
AVP-825 were published in the journal,
. AVP-825 is being developed using OptiNose's novel Breath
Powered intranasal delivery system, which includes low dosages of
) Imitrex (sumatriptan) for the treatment of acute migraine.
The randomized, pharmacokinetic study evaluated the
pharmacokinetics of AVP-825 and compared it with the
pharmacokinetics of three other sumatriptan products: 20 mg
liquid nasal spray, 100 mg oral tablet and 6 mg subcutaneous
Data showed that AVP-825 is highly efficient for delivering
sumatriptan with a higher peak exposure (27%), and greater early
exposure (75%) in the crucial first 15 minutes after treatment
than liquid nasal spray, despite the AVP-825 dose being lower (16
mg). The study also revealed that AVP-825 gave greater overall
intranasal delivery efficiency, with the average total drug
exposure per milligram being one third higher than the total
exposure per milligram achieved with the liquid nasal spray.
Overall, AVP-825 has advantages over other sumatriptan
products currently available to treat migraine as it produces
rapid and efficient medication absorption.
As per the Centers for Disease Control and Prevention, more
than 37 million Americans suffer from migraine headaches.
In Jul 2013, Avanir joined forces with OptiNose for the
development and commercialization of AVP-825 for the treatment of
acute migraine. Once approved, it will be the first and only
fast-acting, dry-powder nasal delivery form of Imitrex.
Avanir currently carries a Zacks Rank #3 (Hold). Companies
that look well-positioned include
Questcor Pharmaceuticals Inc.
), both ofwhich carry a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
AVANIR PHARM (AVNR): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.